SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026.
“We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-founder and CEO of Doximity. “More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”
Fiscal 2027 Second Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended September 30, 2025.
- Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year.
- Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Non-GAAP net income of $68.3 million, versus $90.0 million, representing a margin of 39.1%, versus 53.4%.
- Adjusted EBITDA: Adjusted EBITDA of $88.9 million, versus $100.8 million, a decrease of 12% year-over-year, representing adjusted EBITDA margins of 50.9%, versus 59.8%.
- Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net income per share was $0.36, versus $0.45.
- Operating cash flow and free cash flow: Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1% year-over-year, and free cash flow of $91.3 million, versus $91.6 million, a decrease of less than 1% year-over-year.
Financial Outlook
Doximity is providing guidance for its fiscal third quarter ending December 31, 2026 as follows:
- Revenue between $195 million and $196 million.
- Adjusted EBITDA between $102.5 million and $103.5 million.
Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:
- Revenue between $678 million and $683 million.
- Adjusted EBITDA between $317 million and $325 million.
For more detailed financial commentary, please refer to the “Modeling Considerations” appendix in our prepared remarks.
Conference Call Information
Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The recorded webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians. With AI-powered clinical reference and search capabilities, Doximity helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements are all statements other than statements of historical fact, and specifically include statements regarding guidance and future business and financial results. These statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
DOXIMITY, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(in thousands) | ||||||||
(unaudited) | ||||||||
September 30, 2026 | March 31, 2026 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 218,614 | $ | 219,178 | ||||
Marketable securities | 494,615 | 529,423 | ||||||
Accounts receivable, net | 166,113 | 144,783 | ||||||
Prepaid expenses and other current assets | 42,200 | 50,880 | ||||||
Total current assets | 921,542 | 944,264 | ||||||
Property and equipment, net | 19,827 | 18,080 | ||||||
Deferred income tax assets | 26,070 | 31,984 | ||||||
Operating lease right-of-use assets | 6,362 | 7,140 | ||||||
Intangible assets, net | 31,444 | 35,325 | ||||||
Goodwill | 84,973 | 84,973 | ||||||
Other assets | 1,552 | 1,921 | ||||||
Total assets | $ | 1,091,770 | $ | 1,123,687 | ||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 6,304 | $ | 4,009 | ||||
Accrued expenses and other current liabilities | 35,865 | 42,804 | ||||||
Deferred revenue, current | 100,227 | 106,050 | ||||||
Operating lease liabilities, current | 2,198 | 2,110 | ||||||
Total current liabilities | 144,594 | 154,973 | ||||||
Deferred revenue, non-current | 37 | 400 | ||||||
Operating lease liabilities, non-current | 6,948 | 8,075 | ||||||
Other liabilities, non-current | 11,707 | 9,402 | ||||||
Total liabilities | 163,286 | 172,850 | ||||||
Stockholders' Equity | ||||||||
Preferred stock | — | — | ||||||
Common stock | 178 | 183 | ||||||
Additional paid-in capital | 1,068,702 | 1,001,688 | ||||||
Accumulated other comprehensive income (loss) | (1,653 | ) | 28 | |||||
Accumulated deficit | (138,743 | ) | (51,062 | ) | ||||
Total stockholders’ equity | 928,484 | 950,837 | ||||||
Total liabilities and stockholders’ equity | $ | 1,091,770 | $ | 1,123,687 | ||||
DOXIMITY, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenue | $ | 174,537 | $ | 168,525 | $ | 331,155 | $ | 314,438 | ||||||||
Cost of revenue(1) | 25,346 | 16,425 | 49,038 | 32,218 | ||||||||||||
Gross profit | 149,191 | 152,100 | 282,117 | 282,220 | ||||||||||||
Operating expenses(1): | ||||||||||||||||
Research and development | 41,961 | 30,202 | 80,439 | 57,001 | ||||||||||||
Sales and marketing | 46,892 | 39,168 | 91,941 | 75,533 | ||||||||||||
General and administrative | 16,416 | 19,049 | 32,172 | 31,488 | ||||||||||||
Total operating expenses | 105,269 | 88,419 | 204,552 | 164,022 | ||||||||||||
Income from operations | 43,922 | 63,681 | 77,565 | 118,198 | ||||||||||||
Other income, net | 6,405 | 9,258 | 13,124 | 18,888 | ||||||||||||
Income before income taxes | 50,327 | 72,939 | 90,689 | 137,086 | ||||||||||||
Provision for income taxes | 15,597 | 10,880 | 31,645 | 21,707 | ||||||||||||
Net income | $ | 34,730 | $ | 62,059 | $ | 59,044 | $ | 115,379 | ||||||||
Net income per share attributable to Class A and Class B common stockholders: | ||||||||||||||||
Basic | $ | 0.19 | $ | 0.33 | $ | 0.33 | $ | 0.61 | ||||||||
Diluted | $ | 0.18 | $ | 0.31 | $ | 0.31 | $ | 0.57 | ||||||||
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | ||||||||||||||||
Basic | 178,674 | 187,705 | 180,611 | 187,844 | ||||||||||||
Diluted | 187,804 | 200,745 | 189,475 | 200,952 | ||||||||||||
(1) | Costs and expenses include stock-based compensation expense as follows (in thousands): |
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Cost of revenue | $ | 3,036 | $ | 2,844 | $ | 6,228 | $ | 5,824 | ||||||||
Research and development | 16,028 | 9,862 | 31,587 | 16,511 | ||||||||||||
Sales and marketing | 12,696 | 10,508 | 25,121 | 18,218 | ||||||||||||
General and administrative | 8,805 | 6,260 | 14,381 | 10,786 | ||||||||||||
Total stock-based compensation expense | $ | 40,565 | $ | 29,474 | $ | 77,317 | $ | 51,339 | ||||||||
DOXIMITY, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Cash flows from operating activities | ||||||||||||||||
Net income | $ | 34,730 | $ | 62,059 | $ | 59,044 | $ | 115,379 | ||||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
Depreciation and amortization | 4,353 | 3,469 | 8,640 | 6,263 | ||||||||||||
Stock-based compensation, net of amounts capitalized | 40,565 | 29,474 | 77,317 | 51,339 | ||||||||||||
Non-cash lease expense | 391 | 454 | 778 | 904 | ||||||||||||
Accretion of discount on marketable securities, net | (358 | ) | (2,199 | ) | (925 | ) | (4,687 | ) | ||||||||
Amortization of deferred contract costs | 3,858 | 2,876 | 8,158 | 6,772 | ||||||||||||
Other | 358 | 294 | 20 | (114 | ) | |||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | 11,366 | 12,396 | (21,968 | ) | (985 | ) | ||||||||||
Prepaid expenses and other assets | 5,259 | 7,685 | 14,384 | 3,451 | ||||||||||||
Deferred contract costs | (2,577 | ) | (2,584 | ) | (5,219 | ) | (4,549 | ) | ||||||||
Accounts payable, accrued expenses and other liabilities | 4,701 | (2,168 | ) | 2,268 | (2,333 | ) | ||||||||||
Deferred revenue | (8,834 | ) | (17,241 | ) | (6,186 | ) | (14,268 | ) | ||||||||
Operating lease liabilities | (527 | ) | (571 | ) | (1,039 | ) | (1,127 | ) | ||||||||
Net cash provided by operating activities | 93,285 | 93,944 | 135,272 | 156,045 | ||||||||||||
Cash flows from investing activities | ||||||||||||||||
Cash paid for acquisition, net of cash acquired | — | (26,528 | ) | — | (26,528 | ) | ||||||||||
Purchases of property and equipment | — | — | (62 | ) | — | |||||||||||
Internal-use software development costs | (1,953 | ) | (2,369 | ) | (4,275 | ) | (4,335 | ) | ||||||||
Purchases of marketable securities | (168,476 | ) | (128,266 | ) | (183,222 | ) | (268,200 | ) | ||||||||
Maturities of marketable securities | 86,396 | 125,452 | 212,467 | 270,031 | ||||||||||||
Sales of marketable securities | — | — | 4,049 | — | ||||||||||||
Net cash provided by (used in) investing activities | (84,033 | ) | (31,711 | ) | 28,957 | (29,032 | ) | |||||||||
Cash flows from financing activities | ||||||||||||||||
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants | 908 | 2,398 | 3,988 | 4,796 | ||||||||||||
Proceeds from issuance of common stock in connection with the employee stock purchase plan | 1,288 | 1,816 | 1,288 | 1,816 | ||||||||||||
Taxes paid related to net share settlement of equity awards | (9,948 | ) | (12,566 | ) | (16,922 | ) | (24,493 | ) | ||||||||
Repurchase of common stock | (54,198 | ) | (21,893 | ) | (145,831 | ) | (144,248 | ) | ||||||||
Payment of contingent consideration related to a business combination | — | — | (5,024 | ) | (5,249 | ) | ||||||||||
Payment of excise taxes on share repurchases | (2,292 | ) | — | (2,292 | ) | — | ||||||||||
Net cash used in financing activities | (64,242 | ) | (30,245 | ) | (164,793 | ) | (167,378 | ) | ||||||||
Net increase (decrease) in cash and cash equivalents | (54,990 | ) | 31,988 | (564 | ) | (40,365 | ) | |||||||||
Cash and cash equivalents, beginning of period | 273,604 | 137,261 | 219,178 | 209,614 | ||||||||||||
Cash and cash equivalents, end of period | $ | 218,614 | $ | 169,249 | $ | 218,614 | $ | 169,249 | ||||||||
Supplemental disclosures of cash flow information | ||||||||||||||||
Cash paid for taxes, net of refunds | $ | 10,126 | $ | 14,369 | $ | 14,116 | $ | 19,347 | ||||||||
Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
- Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
- Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
- Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment, purchases of intangible assets, and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics
- Net revenue retention rate: Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
- Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business and the value we create for large customers, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.
- Quarterly unique active providers using our workflow tools: Quarterly unique active providers1 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely log in and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.
__________________________ | ||
1 | Providers are health care professionals with clinical / prescribing roles, specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetists (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students. | |
Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||
Net income | $ | 34,730 | $ | 62,059 | $ | 59,044 | $ | 115,379 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Acquisition and other related expenses | — | 1,188 | — | 1,616 | ||||||||||||
Stock-based compensation | 40,565 | 29,474 | 77,317 | 51,339 | ||||||||||||
Depreciation and amortization | 4,353 | 3,469 | 8,640 | 6,263 | ||||||||||||
Provision for income taxes | 15,597 | 10,880 | 31,645 | 21,707 | ||||||||||||
Change in fair value of contingent earn-out consideration liability | — | 91 | 90 | 259 | ||||||||||||
Legal expenses | 25 | 2,927 | 25 | 2,927 | ||||||||||||
Other income, net | (6,405 | ) | (9,258 | ) | (13,124 | ) | (18,888 | ) | ||||||||
Adjusted EBITDA | $ | 88,865 | $ | 100,830 | $ | 163,637 | $ | 180,602 | ||||||||
Revenue | $ | 174,537 | $ | 168,525 | $ | 331,155 | $ | 314,438 | ||||||||
Net income margin | 20 | % | 37 | % | 18 | % | 37 | % | ||||||||
Adjusted EBITDA margin | 51 | % | 60 | % | 49 | % | 57 | % | ||||||||
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(unaudited) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Net cash provided by operating activities | $ | 93,285 | $ | 93,944 | $ | 135,272 | $ | 156,045 | ||||||||
Purchases of property and equipment | — | — | (62 | ) | — | |||||||||||
Internal-use software development costs | (1,953 | ) | (2,369 | ) | (4,275 | ) | (4,335 | ) | ||||||||
Free cash flow | $ | 91,332 | $ | 91,575 | $ | 130,935 | $ | 151,710 | ||||||||
Other cash flow components: | ||||||||||||||||
Net cash provided by (used in) investing activities | $ | (84,033 | ) | $ | (31,711 | ) | $ | 28,957 | $ | (29,032 | ) | |||||
Net cash used in financing activities | $ | (64,242 | ) | $ | (30,245 | ) | $ | (164,793 | ) | $ | (167,378 | ) | ||||
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except per share data and percentages) | ||||||||||||||||
GAAP cost of revenue | $ | 25,346 | $ | 16,425 | $ | 49,038 | $ | 32,218 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Stock-based compensation | (3,036 | ) | (2,844 | ) | (6,228 | ) | (5,824 | ) | ||||||||
Amortization of acquired intangibles | (935 | ) | — | (1,870 | ) | — | ||||||||||
Non-GAAP cost of revenue | $ | 21,375 | $ | 13,581 | $ | 40,940 | $ | 26,394 | ||||||||
GAAP gross profit | $ | 149,191 | $ | 152,100 | $ | 282,117 | $ | 282,220 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Stock-based compensation | 3,036 | 2,844 | 6,228 | 5,824 | ||||||||||||
Amortization of acquired intangibles | 935 | — | 1,870 | — | ||||||||||||
Non-GAAP gross profit | $ | 153,162 | $ | 154,944 | $ | 290,215 | $ | 288,044 | ||||||||
GAAP gross margin | 85.5 | % | 90.3 | % | 85.2 | % | 89.8 | % | ||||||||
Non-GAAP gross margin | 87.8 | % | 91.9 | % | 87.6 | % | 91.6 | % | ||||||||
GAAP research and development expense | $ | 41,961 | $ | 30,202 | $ | 80,439 | $ | 57,001 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Stock-based compensation | (16,028 | ) | (9,862 | ) | (31,587 | ) | (16,511 | ) | ||||||||
Amortization of acquired intangibles | — | (623 | ) | — | (623 | ) | ||||||||||
Non-GAAP research and development expense | $ | 25,933 | $ | 19,717 | $ | 48,852 | $ | 39,867 | ||||||||
GAAP sales and marketing expense | $ | 46,892 | $ | 39,168 | $ | 91,941 | $ | 75,533 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Stock-based compensation | (12,696 | ) | (10,508 | ) | (25,121 | ) | (18,218 | ) | ||||||||
Amortization of acquired intangibles | (1,005 | ) | (1,002 | ) | (2,011 | ) | (2,004 | ) | ||||||||
Change in fair value of contingent earn-out consideration liability | — | (91 | ) | (90 | ) | (259 | ) | |||||||||
Non-GAAP sales and marketing expense | $ | 33,191 | $ | 27,567 | $ | 64,719 | $ | 55,052 | ||||||||
GAAP general and administrative expense | $ | 16,416 | $ | 19,049 | $ | 32,172 | $ | 31,488 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Acquisition and other related expenses | — | (1,188 | ) | — | (1,616 | ) | ||||||||||
Stock-based compensation | (8,805 | ) | (6,260 | ) | (14,381 | ) | (10,786 | ) | ||||||||
Legal expenses | (25 | ) | (2,927 | ) | (25 | ) | (2,927 | ) | ||||||||
Non-GAAP general and administrative expense | $ | 7,586 | $ | 8,674 | $ | 17,766 | $ | 16,159 | ||||||||
GAAP operating expense | $ | 105,269 | $ | 88,419 | $ | 204,552 | $ | 164,022 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Acquisition and other related expenses | — | (1,188 | ) | — | (1,616 | ) | ||||||||||
Stock-based compensation | (37,529 | ) | (26,630 | ) | (71,089 | ) | (45,515 | ) | ||||||||
Amortization of acquired intangibles | (1,005 | ) | (1,625 | ) | (2,011 | ) | (2,627 | ) | ||||||||
Change in fair value of contingent earn-out consideration liability | — | (91 | ) | (90 | ) | (259 | ) | |||||||||
Legal expenses | (25 | ) | (2,927 | ) | (25 | ) | (2,927 | ) | ||||||||
Non-GAAP operating expense | $ | 66,710 | $ | 55,958 | $ | 131,337 | $ | 111,078 | ||||||||
GAAP operating income | $ | 43,922 | $ | 63,681 | $ | 77,565 | $ | 118,198 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Acquisition and other related expenses | — | 1,188 | — | 1,616 | ||||||||||||
Stock-based compensation | 40,565 | 29,474 | 77,317 | 51,339 | ||||||||||||
Amortization of acquired intangibles | 1,940 | 1,625 | 3,881 | 2,627 | ||||||||||||
Change in fair value of contingent earn-out consideration liability | — | 91 | 90 | 259 | ||||||||||||
Legal expenses | 25 | 2,927 | 25 | 2,927 | ||||||||||||
Non-GAAP operating income | $ | 86,452 | $ | 98,986 | $ | 158,878 | $ | 176,966 | ||||||||
GAAP net income | $ | 34,730 | $ | 62,059 | $ | 59,044 | $ | 115,379 | ||||||||
Adjusted to exclude the following: | ||||||||||||||||
Acquisition and other related expenses | — | 1,188 | — | 1,616 | ||||||||||||
Stock-based compensation | 40,565 | 29,474 | 77,317 | 51,339 | ||||||||||||
Amortization of acquired intangibles | 1,940 | 1,625 | 3,881 | 2,627 | ||||||||||||
Change in fair value of contingent earn-out consideration liability | — | 91 | 90 | 259 | ||||||||||||
Legal expenses | 25 | 2,927 | 25 | 2,927 | ||||||||||||
Income tax effect of non-GAAP adjustments (1) | (8,931 | ) | (7,414 | ) | (17,076 | ) | (12,341 | ) | ||||||||
Non-GAAP net income | $ | 68,329 | $ | 89,950 | $ | 123,281 | $ | 161,806 | ||||||||
Non-GAAP net income margin | 39.1 | % | 53.4 | % | 37.2 | % | 51.5 | % | ||||||||
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | ||||||||||||||||
Basic | 178,674 | 187,705 | 180,611 | 187,844 | ||||||||||||
Diluted | 187,804 | 200,745 | 189,475 | 200,952 | ||||||||||||
Non-GAAP net income per share attributable to Class A and Class B stockholders: | ||||||||||||||||
Basic | $ | 0.38 | $ | 0.48 | $ | 0.68 | $ | 0.86 | ||||||||
Diluted | $ | 0.36 | $ | 0.45 | $ | 0.65 | $ | 0.81 | ||||||||
(1) | For the three and six months ended September 30, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%. |